Results about: cirrhosis
The Asociación Española Contra el Cáncer (AECC) presents a prize for a study that reveals the capacity of the CPEB4 protein to prevent fatty liver disease.
The research was led by Raúl Méndez from IRB Barcelona and Mercedes Fernández from IDIBAPS.
What prompts two medical doctors, after six years of training and five years of specialisation, to pursue a PhD? It’s simple: translational medicine.
It is a disease of the liver caused by excessive fat deposits in liver cells.
It is now the most prevalent chronic liver disease in industrialised countries and is a major public health concern because it leads to serious liver conditions.
A study by IRB Barcelona and IDIBAPS reveals a therapeutic target to prevent the development of the many abnormal blood vessels that cause gastrointestinal bleeding—the main complication in cirrhosis.
Cirrhosis is the main risk factor for liver cancer. The same target may be the key to preventing and treating this condition.
Cirrhosis figures among the top twenty causes of death from disease worldwide.